Endolaserless vitrectomy with IAI leads to long-term visual gains in diabetic retinopathy
Long-term visual gains after endolaserless vitrectomy with intravitreal aflibercept injection (IAI) monotherapy in patients with proliferative diabetic retinopathy (PDR)-related vitreous hemorrhage (VH) are possible, according to a study.
In the study, eyes received 1 preoperative IAI and 1 intraoperative IAI during endolaserless vitrectomy. Eyes were then randomized to a q8week (n = 14) or q16week (n = 17) IAI group. Additional IAI was administered as needed.
Through approximately 3 years, eyes in the q8week group received 18.6 IAIs and eyes in the q16week group received 12.1 IAIs.
There was a visual acuity increase of 34 letters in the Q8week eyes (P = 0.003) compared to a 27-letter increase in the q16week eyes (P = 0.013).
The authors concluded that more frequent IAIs are required for fewer proliferative consequences.
Reference
Kasetty VM, Starnes DC, Sood N, et al. Complications, Compliance, and 3-Year Outcomes After Endolaserless Vitrectomy With Aflibercept Monotherapy for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage. Ophthalmic Surg Lasers Imaging Retina. 2023;54(2):89-96. doi: 10.3928/23258160-20221216-02. Epub 2023 Feb 1. PMID: 36780633.
